儿科急性淋巴细胞白血病:对当前知识和进展的叙述性审查
Sarah Elgazar1, Constantina Constantinou2
1Department of Basic and Clinical Sciences, University of Nicosia Medical School, 21 Ilia Papakyriakou, 2414 Engomi, P.O. Box 24005, CY-1700, Nicosia, Cyprus.
Current oncology reports
|November 6, 2024
概括
诊断和治疗儿科急性淋巴细胞白血病 (ALL) 的进展使得生存率提高到90%. 持续的研究和全球医疗保健准入对于进一步推进儿童ALL治疗和预防至关重要.
科学领域:
- 儿科瘤学 儿科瘤学
- 血液学 血液学 血液学
- 癌症基因组学 癌症基因组学
背景情况:
- 急性淋巴细胞白血病 (ALL) 是最常见的儿童癌症.
- 显著的进步导致了90%的儿童ALL存活率.
- 了解ALL的异质性是有效管理的关键.
研究的目的:
- 更新有关儿童ALL诊断和治疗的知识.
- 突出最近的进展和未来的方向.
- 为了解决全球在ALL护理方面的差异.
主要方法:
- 审查当前的诊断算法 (形态,免疫类型,细胞遗传).
- 新兴诊断技术 (NGS,AI) 的探索.
- 对ALL的当前和新型治疗策略的分析.
主要成果:
- 儿童ALL存活率达到90%由于进步.
- 精确诊断对于个性化风险分层和治疗至关重要.
- 新型治疗方法 (TKIs,CAR T细胞,blinatumomab) 改善了高风险/复发ALL的治疗结果.
- 全球获得医疗保健仍然是一个重大障碍.
结论:
- 持续的研究和临床试验对于改善ALL治疗疗效和预防至关重要.
- 整合新的诊断和治疗方法至关重要.
- 解决全球医疗保健差距对于公平的儿科ALL结果至关重要.
相关概念视频
Bone Marrow Sampling and Transplants
292
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
292
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


